Unknown

Dataset Information

0

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.


ABSTRACT: After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a surrogate measure for long-term outcomes, therefore offering the ability for early and objective assessment of treatment efficacy and the potential to inform and personalize adjuvant treatment clinical decision-making. Leveraging the neoadjuvant treatment setting offers the ability to deeply interrogate longitudinal tissue in order to gain translatable, pan-malignancy insights into response and mechanisms of resistance to immunotherapy. Neoadjuvant immunotherapy across cancers was a focus of discussion at the virtual Immunotherapy Bridge meeting (December 1-2, 2021). Clinical, biomarker, and pathologic insights from prostate, breast, colon, and non-small-cell lung cancers, melanoma and non-melanoma skin cancers were discussed and are summarized in this report.

SUBMITTER: Burton EM 

PROVIDER: S-EPMC9199148 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.

Burton Elizabeth M EM   Amaria Rodabe N RN   Cascone Tina T   Chalabi Myriam M   Gross Neil D ND   Mittendorf Elizabeth A EA   Scolyer Richard A RA   Sharma Padmanee P   Ascierto Paolo A PA  

Journal of translational medicine 20220615 1


After the success of immunotherapy in the treatment of advanced metastatic cancer, further evaluation in earlier settings, including high-risk, surgically-resectable disease is underway. Potential benefits of a neoadjuvant immunotherapeutic approach include presurgical tumor shrinkage, reduced surgical morbidity, early eradication of micrometastases and prevention of distant disease, and greater antigen-specific T cell response. For some cancers, pathologic response has been established as a sur  ...[more]

Similar Datasets

| S-EPMC9172186 | biostudies-literature
| S-EPMC10360352 | biostudies-literature
| S-EPMC8173810 | biostudies-literature
| S-EPMC10375730 | biostudies-literature
| S-EPMC5067891 | biostudies-literature
| S-EPMC8981597 | biostudies-literature
| S-EPMC7789268 | biostudies-literature
| S-EPMC5905181 | biostudies-literature
| S-EPMC8243582 | biostudies-literature